OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC Logo

OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC

A former biopharma firm that developed non-addictive, cannabinoid-based pain therapies.

OCTHF | IL

Overview

Corporate Details

ISIN(s):
GB00BMVMRB86
LEI:
2138005SRWT4998BCE35
Country:
United Kingdom
Address:
PRAMA HOUSE, 267 BANBURY ROAD, OX2 7HT OXFORD
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

As of May 2025, Oxford Cannabinoid Technologies Holdings PLC has ceased trading and entered administration. Prior to this, the company operated as a clinical-stage biopharmaceutical firm engaged in the research, development, and commercialization of cannabinoid-based prescription medicines. The company focused on developing non-addictive therapies for the pain market, aiming to provide an alternative to opioids. Its drug discovery programs targeted the Endocannabinoid System (ECS) with a portfolio of proprietary derivatives, in-licensed compounds, and new chemical entities.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-06-06 08:00
Delisting Announcement
Cancellation of Listing
English 10.0 KB
2024-05-31 08:00
Delisting Announcement
Updated Shareholder Engagement
English 10.6 KB
2024-05-17 17:30
Delisting Announcement
Updated Shareholder Information
English 22.6 KB
2024-05-08 08:00
Delisting Announcement
Intended Cancellation of Listing
English 32.1 KB
2024-04-11 12:26
Report Publication Announcement
Appointment of Phase I Clinical Trial CRO
English 17.3 KB
2024-04-03 09:00
Regulatory News Service
OCT Company Update with Doceo
English 7.4 KB
2024-03-26 11:56
Report Publication Announcement
Oxford Cannabinoid Technologies video with Doceo
English 6.9 KB
2024-03-18 08:00
Regulatory News Service
Appointment of Hybridan as Adviser
English 14.2 KB
2024-02-29 08:02
Board/Management Information
Directorate Appointment
English 15.3 KB
2024-02-29 08:01
Board/Management Information
Directorate Changes
English 16.2 KB
2024-02-29 08:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 11.8 KB
2024-02-28 18:35
Major Shareholding Notification
TR-1: NOTIFICATION OF MAJOR HOLDINGS
English 65.2 KB
2024-02-28 18:34
Major Shareholding Notification
TR-1: NOTIFICATION OF MAJOR HOLDINGS
English 71.7 KB
2024-02-28 18:34
Major Shareholding Notification
TR-1: NOTIFICATION OF MAJOR HOLDINGS
English 65.4 KB
2024-02-26 14:07
Director's Dealing
Directors’ Dealings
English 40.8 KB

Automate Your Workflow. Get a real-time feed of all OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.